A recent post on Bruce's blog looks promising.

Tolfenamic acid (TA) and 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole (MEPB) (oh my!) are the two drugs discussed. Another link

Looks like they are working down on the gene level.

Pharmaceutical companies have been developing drugs to target this small patch, called the "activator function-2" or "AF2" domain. The companies were testing the drugs as possible treatments for prostate cancer, which also involves the androgen receptor. Taylor obtained a collection of the test drugs to evaluate for use with SBMA.

Probably good news that the drugs may work for prostate cancer, that is a much larger population than ours, which may justify the clinical trials.

Works on our brother flies and mice! The word "treatment" appears, but they could be out over their skis on that.

Fingers crossed!